IL17A and rheumatoid arthritis: These findings suggest that an important subgroup of RA patients express high IL-23/IL-17 cytokines, introducing the potential of stratification of patients by ELN in exploratory clinical trial for anti-IL23 or anti-IL-17 antibodies.